0001213900-19-000817.txt : 20190116 0001213900-19-000817.hdr.sgml : 20190116 20190116184915 ACCESSION NUMBER: 0001213900-19-000817 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180114 FILED AS OF DATE: 20190116 DATE AS OF CHANGE: 20190116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Erony Joyce CENTRAL INDEX KEY: 0001459212 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38468 FILM NUMBER: 19529871 MAIL ADDRESS: STREET 1: C/O IGI LABORATORIES, INC. STREET 2: 105 LINCOLN AVENUE CITY: BUENA STATE: NJ ZIP: 08310 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inspire Medical Systems, Inc. CENTRAL INDEX KEY: 0001609550 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 261377674 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9700 63RD AVENUE N STREET 2: SUITE 200 CITY: MAPLE GROVE STATE: X1 ZIP: 55369 BUSINESS PHONE: 763-205-7970 MAIL ADDRESS: STREET 1: 9700 63RD AVENUE N STREET 2: SUITE 200 CITY: MAPLE GROVE STATE: X1 ZIP: 55369 4 1 ownership.xml OWENERSHIP DOCUMENT X0306 4 2018-01-14 0 0001609550 Inspire Medical Systems, Inc. INSP 0001459212 Erony Joyce C/O INSPIRE MEDICAL SYSTEMS, INC. 9700 63RD AVENUE NORTH, SUITE 200 MAPLE GROVE MN 55369 1 0 0 0 Common Stock 2018-01-14 4 S 0 88000 48.6866 D 1409043 I See Footnote Common Stock 2018-01-15 4 S 0 2000 48.0269 D 1407043 I See Footnote Common Stock 2018-01-15 4 S 0 90000 48.8176 D 1317043 I See Footnote Common Stock 2018-01-15 4 S 0 22568 49.2684 D 1294475 I See Footnote Common Stock 2018-01-16 4 S 0 30704 50.8255 D 1263771 I See Footnote Common Stock 2018-01-16 4 S 0 67432 50.1336 D 1196339 I See Footnote The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.515 to $49.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.11 to $48.37. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.11 to $49.43. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.945 to $49.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.455 to $51.435. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.23 to $51.26. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. The reporting person disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein. /s/ Joyce Erony 2019-01-16